Full Scientific Exchange About an Investigational Drug Is Not Restricted

Rule

The restriction in 21 CFR 312.7(a) — which applies to a sponsor or investigator, or any person acting on behalf of a sponsor or investigator — on promoting an investigational new drug (or, for an approved product, on promoting the new use under investigation; it does not reach the approved indication) does not limit legitimate scientific exchange about the drug, including publication of scientific findings in scientific or lay media. For purposes of 21 CFR 312.7(a), the carve-out turns on whether the piece makes promotional claims of safety or effectiveness for the investigated use or otherwise promotes or commercializes the drug; this provision does not itself impose a balance requirement. Obligations arising under other authorities (e.g., truthful and non-misleading requirements) are outside the scope of this rule.

Check

For pieces disseminating scientific findings on an investigational drug, or on an investigational new use of an approved product, that are authored, sponsored, or distributed by a sponsor or investigator (or anyone acting on their behalf), confirm the piece does not represent, in a promotional context, that the drug is safe or effective for the use under investigation, and does not otherwise promote the drug or serve to commercialize it before approval for that use. A violation is a promotional-context claim of safety/effectiveness for the investigated use, or content that otherwise functions to promote or commercialize the drug pre-approval; the mere absence of a discussion of limitations, methods, or results is not itself a violation of 21 CFR 312.7(a) (though it may implicate obligations under other authorities not addressed by this rule).

Escalate when

The line between permissible scientific dissemination and a prohibited promotional claim or act of commercialization under 21 CFR 312.7(a) is unclear from tone, audience, or context — e.g., whether the actor is a sponsor/investigator or someone acting on their behalf, or whether the content concerns the investigated use versus an already-approved indication; escalate for judgment.